Browse drugs

…treatment samples and in responders.Conclusions Lenvatinib plus pembrolizumab demonstrated encouraging efficacy when used as neoadjuvant ther…

… 30% variation across strata, and a 60% hazard reduction due to aspirin, the required sample size to achieve 80% power is 760 patients.…

…sclerosis. 3 days after receiving her first dose of intravenous Ig, she developed a pruritic rash in her intertriginous regions of…

…gainst human SW1990 pancreatic tumor cell line when compared to pembrolizumab. HCW11-040 was also found to neutralize the immunosuppresivenes…

…red NK cells to express a B7-H3.CAR alongside a tumor-cleavable anti-PD-L1 scFv demonstrated significantly enhanced cytotoxicity against OS cel…

…rammed iAPCs and GFP-transduced controls were then treated with temozolomide (100µM, 72h) or TTFields (200kHz, 1.5V/cm, 72h), and pyroptosis…

…de combination ipilimumab and nivolumab, nivolumab monotherapy, pembrolizumab, and combination relatimab and nivolumab. Regarding hospitaliza…

…112-pixels) to train a vision transformer model (ViT-B/16)6 for PD-L1 binary classification (figure 1).Results Our Pix2Pix GAN model …

…ytotoxicity data from three TCEs (teclistamab, elranatamab, and epcoritamab). Hypothetical experiments were simulated to explore possible i…

…ROP2, or EGFR Boosters demonstrated superior tumor control than trastuzumab, sacituzumab, or cetuximab analogue treated mice respectively. …

…d outperformed other KRAS pathway inhibitors like Sotorasib and Zoldonrasib, without selectivity to specific KRAS mutations. TRIM7 specific…

…ter than a traditional T-cell engager. The CD40-directed arm of APVO451 led to the induction of IL-12 secretion and upregulation of CD8…